EMA Authorised: Waylivra (volanesorsen sodium) — Akcea Therapeutics Ireland Limited

View source ↗

Summary

The European Medicines Agency authorised Waylivra (volanesorsen) for Hyperlipoproteinemia Type I, under conditional approval with orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipoproteinemia Type

Drugs mentioned

• Waylivra (volanesorsen)

Snippet

Status: Authorised. Therapeutic area: Hyperlipoproteinemia Type I. MAH: Akcea Therapeutics Ireland Limited. Decision date: 11/07/2025. Conditional approval. Orphan medicine